Skip to main content
. Author manuscript; available in PMC: 2022 May 24.
Published in final edited form as: Bioorg Med Chem. 2021 Sep 17;48:116414. doi: 10.1016/j.bmc.2021.116414

Fig. 1.

Fig. 1.

The design of novel phenylalanine derivatives as HIV-1 CA inhibitors (a) Structure and the binding mode of PF-74 in the NTD-CTD interface of CA protein hexamer (PDB code: 5HGL). Red dashed lines indicate H-bond interactions. (b) Several reported phenylalanine derivatives as HIV-1 CA protein inhibitors in our lab. (c) Target compounds designed in this work. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)